newsfilter
← Latest News
Business Wire·

Tessera Therapeutics Announces Over $300M Series C Financing to Advance its GENE WRITING Platform

Latest Financing Round Will Support Tessera's Build Out of its GENE WRITING Platforms and Pursuit of Multiple Therapeutic Programs for Clinical Development Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine